Lindsay Martin

Person

Heard in 3 episodes across 1 show since Oct 2026

Lindsay Martin is a life sciences analyst and writer associated with BioCentury, focusing on biotechnology innovation and company performance.

Episodes

across 1 show

First heard

Oct 2026

Guest appearances

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data

Email alert

One email a week at most, with the new episodes that mention Lindsay Martin. Free, no account needed, unsubscribe in one click.

3 statements

on COINS ActNegativeNov 3, 2026· BioCentury This Week
Some U.S. newco deals licensing Chinese assets may fall under COINS rules.
“new co-deals where a Western investor or US investor is launching a company in the US with an asset in license from China may fall into this scope”
Listen at 20:25
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposal
on COINS ActMixedNov 3, 2026· BioCentury This Week
COINS restrictions may create some benefits for U.S. investors.
“this may not be all bad news”
Listen at 20:47
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposal
on Disclosed newco dealsNeutralNov 3, 2026· BioCentury This Week
Nearly two-thirds of disclosed newco deals included equity stakes.
“nearly two thirds of those did involve equity stakes”
Listen at 23:51
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposal

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

3 episodes featuring Lindsay Martin, newest first